Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era

BACKGROUND: In response to the critical shortage of Doxil(®), the US Food and Drug Administration (FDA) allowed temporary importation of non-FDA-approved second-generation liposomal doxorubicin, Lipo-Dox(®). Lipo-Dox utilizes a different liposomal particle than Doxil and demonstrates different pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Jessica L, Smith, Ashlee, Zorn, Kristin K, Sukumvanich, Paniti, Olawaiye, Alexander B, Kelley, Joseph, Krivak, Thomas C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133030/
https://www.ncbi.nlm.nih.gov/pubmed/25143745
http://dx.doi.org/10.2147/OTT.S62881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133030/
https://www.ncbi.nlm.nih.gov/pubmed/25143745
http://dx.doi.org/10.2147/OTT.S62881

Ejemplares similares